Stockpolly
Search
Delisting risk
CTXR · NASDAQ · Biotechnology

Citius Pharmaceuticals (CTXR)

Commercializes LYMPHIR for cutaneous T-cell lymphoma while developing infection, hemorrhoid, and cell-therapy programs.

$0.5800
Pre-market−0.00 (−0.84%)
At close$0.5849(+2.78%)
Watchlist

In millions of USD, except per-share figures

In millionsQ4 FY23Sep 2023Q1 FY24Dec 2023Q2 FY24Mar 2024Q3 FY24Jun 2024Q4 FY24Sep 2024Q1 FY25Dec 2024Q2 FY25Mar 2025Q3 FY25Jun 2025Q4 FY25Sep 2025Q1 FY26Dec 2025Q2 FY26Mar 2026Q3 FY26Jun 2026
Revenue000000000421
Cost of revenue000000000122
Gross profit00000000030−1
109111111101198123211
Research & development334332422221
77788877162610
General & administrative7778087716260
Other expenses000000006440
Operating income−10−9−11−11−11−10−11−9−8−9−32−12
003000000040
Interest income000000000000
Interest expense000000000000
Other non-operating income000000000000
Income before tax−10−9−8−10−11−10−11−9−8−9−28−12
Income tax expense000000000000
Net income from continuing operations−10−9−9−11−11−10−12−9−9−9−28−12
Net income−10−9−9−11−11−10−11−9−8−8−21−9
EPS, basic−$0.06−$1.45−$1.34−$1.57−$0.99−$1.30−$1.27−$0.80−$0.44−$0.38−$0.95−$0.34
EPS, diluted−$0.06−$1.45−$1.34−$1.57−$0.99−$1.30−$1.27−$0.80−$0.44−$0.38−$0.95−$0.34
Weighted average shares, basic11611121212121118212226
Weighted average shares, diluted11611121212121118212226
EBITDA−10−9−11−11−11−10−11−9−8−8−30−10
Depreciation & amortization000000000122
EBIT−10−9−11−11−11−10−11−9−8−9−32−12